GSK3 inhibition, ATP competition and tested kinase selectivity
Biochemical assay · Recombinant human GSK3 enzyme assays; CDK2/cyclin E, CDK5 and a 26-kinase comparator panel [1]
AR-A014418 inhibited GSK3 and showed ATP-competitive kinetics. Selectivity applies to the tested enzymes and assay conditions; this is not proof of GSK3β isoform selectivity or exclusion of other targets.
| Endpoint | Reported result | Reference |
|---|---|---|
| Inhibition of recombinant human GSK3 activity | IC50 104 ± 27 nM (mean ± S.E.; three independent experiments, each in duplicate) | [1] |
| ATP-competitive inhibition of GSK3 | Ki 38 nM | [1] |
| Inhibition of CDK2 and CDK5 | IC50 >100 µM for each enzyme | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- SPA reaction: 20 min at room temperature; kinetic assay: 15 min at room temperature
- Method
- Radiometric scintillation proximity assay using eIF2B-derived peptide; separate glycogen-synthase-peptide kinetic assay; no-substrate blanks and activity without compound as controls
- Vehicle
- DMSO for kinase panel; no-compound controls for concentration-response assays
- Reported limits
- Final DMSO fraction in enzyme concentration-response assays not established in selected text. IC50 is an endpoint, not a treatment concentration.
Methods and source locations
Compound reported in the paper: AR-A014418
Compound-level research evidence; tested materials do not establish performance or identity of an Adooq lot.
Fig. 1A–E and caption, pp. 45940–45941; Kinase Assays and Kinetic Studies, p. 45939; IC50 Determination, p. 45940
Inhibition of recombinant human GSK3 activity: eIF2B-peptide SPA at 1 µM ATP; kinase activity normalized to activity without inhibitor — Fig. 1B caption, p. 45941; GSK3 SPA, p. 45939
ATP-competitive inhibition of GSK3: Nonlinear regression of ATP/inhibitor matrix; separate GS-peptide kinetic assay — Fig. 1D–E caption, p. 45941; Kinetic Studies, p. 45939
Inhibition of CDK2 and CDK5: Separate radiometric kinase concentration-response assays; not extrapolated to CDK12/CDK13 — Fig. 1B and caption, p. 45941